TGA Approves New Treatment to Delay Type 1 Diabetes Onset in Australia
27 May 2026
The Therapeutic Goods Administration (TGA) has approved teplizumab, sold as Tzield, for adults and children aged eight years and older who have stage 2 type 1 diabetes. The treatment is designed to delay the development of stage 3 type 1 diabetes, when symptoms usually appear and insulin treatment becomes necessary.
Tzield works by slowing the immune system attack that causes type 1 diabetes. Studies show it can delay the condition by an average of two years.
The medicine is not yet available through the Pharmaceutical Benefits Scheme (PBS), but its manufacturer has submitted it for funding consideration.
Diabetes experts have welcomed the approval, saying it gives patients and families more time to prepare for the condition, access specialist care, and receive support before symptoms begin.
More than 145,000 Australians live with type 1 diabetes, while around 25,000 people may be living with the early stages of the disease without knowing it.
Experts say screening is the only way to identify people who may benefit from Tzield before symptoms develop. The approval also highlights the important role of GPs in identifying people at risk and supporting families through early intervention and monitoring.
Tzield has already been approved in several countries, including the United States, the United Kingdom, Canada, China and across the European Union.
Categories
- MBS
- PBS
- The Department Of Health And Aged Care
- RACGP
- NIP
- AHPRA
- NSW Health
- Queensland Health
- Victoria Health
- Tasmania News
- Western Australia
- SA Health
- NT HEALTH
- Pharmacy Board Of Ahpra
- National Asthma Council
- NT
- AMA
- NACCHO
- BCNA
- Australian College Of Nurse Practitioners
- Asthma Australia
- LFA
- Palliative Care
- Primary Health Network
- AIHW
- Children's Health Queenland
- Kidney Health
- CHF
- MHC
- Gold Coast
- Tsa
- TGA
Popular Posts
Recent Posts
Tags
- Environmental health National Health and Climate Strategy environmental-health-national-health-and-climate-strategy